Clinical trial
Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial
NCT05280405 is registered in ClinicalTrials.gov with IRCCS Burlo Garofolo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial
- Lead sponsor
- IRCCS Burlo Garofolo
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- March 9, 2022
- Completion date
- January 31, 2025
- Enrollment
- 86 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.